Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610244 | 0.82 | MRGPRX4 (0.40) | KDRTHRBBRAFMAPK14TNNI3K | |
| SCHEMBL21610256 | 0.79 | MAP4K4 (0.40) | KDRBRAFMAPK14TNNI3KMAP4K4 | |
| SCHEMBL6938479 | 0.77 | KDR (0.48) | KDRBRAFFLT1FLT4TRPV1 | |
| SCHEMBL21610233 | 0.77 | KDR (0.47) | KDRMAP4K4PDGFRBPDGFRA | |
| SCHEMBL21610197 | 0.75 | KDR (0.45) | KDRMAPK14TNNI3KMAP4K4PDGFRB | |
| SCHEMBL7885594 | 0.74 | KDR (0.46) | KDRBRAFFLT1FLT4TRPV1 | |
| SCHEMBL8773800 | 0.71 | KDR (0.48) | KDRBRAFFLT1FLT4KCNH2 | |
| SCHEMBL7781852 | 0.71 | KDR (0.48) | KDRBRAFFLT1FLT4KCNH2 | |
| SCHEMBL8439101 | 0.71 | KDR (0.44) | KDRBRAFFLT1FLT4TRPV1 | |
| SCHEMBL21610170 | 0.71 | HAO1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947365-B1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-11-12 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3947365-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | Bionomics Limited (AU) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | KDR 4670/4885CYP11B2 881/4885CYP11B1 1498/4885 |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | SCN3A, KCND3, GRIN3A | KDR 4056/4885CYP11B2 2376/4885CYP11B1 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.